載入...
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...
Na minha lista:
| 發表在: | Endocr Connect |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Bioscientifica Ltd
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7576644/ https://ncbi.nlm.nih.gov/pubmed/33064663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-20-0342 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|